The combination of natural-derived vitamin K2 with octacosanol (the main constituent of policosanol) could contribute to lowering levels of cholesterol, triglycerides, LDL-cholesterol, and its combination with a statin can achieve the target value of LDL- and HDL-cholesterol, say a new study published by Jovanovic et al in International Journal of Pharmaceutical Science and Invention.
The study was conducted as a prospective clinical study and included a total of 6595 subjects. The study group included 4031 subjects (1785 males and 2246 females) who were taking a combination of natural Vitamin K2/MK7 from Bacillus subtilis Natto 45μg , vitaMK7® (by Gnosis, Italy) with 20 mg of Octacosanol under the brand name of ARTEROprotect® (by Abela Pharm, Serbia) while the control group compromised 2564 subjects (1135 males and 1428 females) who were not taking it.
The study was conducted by 76 doctors – general practitioners, specialists in internal medicine and cardiology – in in primary health centers throughout the Republic of Serbia, in accordance with the principles of good clinical practice and the Declaration of Helsinki.
Based on the results, it can be said that dietary supplement ARTEROprotect® used alone can contribute to lowering levels of blood fat, and in combination with a statin it can achieve the target value of HDL-cholesterol.
Vitamin K2-MK7 used for ARTEROprotect® is obtained by a patented biofermentation process (property of Gnosis Spa) which ensures a high yield of the natural vitamin K2. VitaMK7® offers the highest content of all-trans MK7, free from solvents and chemicals and in compliance with USP Pharmacopeia. The high purity and stability profile allow the powder to be used as is, without applying coating or chemical microencapsulation.
